Video

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

Author(s):

Kami J. Maddocks, MD,Alexey V. Danilov, MD, PhD

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

Related Videos
Leo I. Gordon, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
BTK Inhibitors in Late-Relapse Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com
November 19th 2024

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Michael Wang, MD
November 5th 2024

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

Michael Wang, MD
October 22nd 2024

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

CAR T-Cell Therapy in R/R Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com
October 14th 2024

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma